HB Wealth Management LLC Has $2.94 Million Position in Danaher Co. (NYSE:DHR)

HB Wealth Management LLC cut its position in Danaher Co. (NYSE:DHR) by 3.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,803 shares of the conglomerate’s stock after selling 479 shares during the quarter. HB Wealth Management LLC’s holdings in Danaher were worth $2,939,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the 4th quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher during the 3rd quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 1.4 %

Danaher stock opened at $238.41 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The firm’s fifty day moving average is $234.85 and its 200 day moving average is $253.42. The company has a market capitalization of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts predict that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s payout ratio is 20.61%.

Analyst Ratings Changes

Several brokerages recently issued reports on DHR. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Royal Bank of Canada reduced their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Guggenheim assumed coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.